Hepatitis B and C Therapeutics Market Surges to US$17.02 Billion in 2024 as Innovation, National Screening Policies, and Next-Gen Antivirals Transform Global Care | According to DataM Intelligence

AUSTIN, Texas and TOKYO, Nov. 19, 2025 /PRNewswire/ -- The Hepatitis B and C Therapeutics Market has entered a renewed growth cycle in 2024, led by innovative antiviral regimens, expanded national vaccination programs, accelerated screening, and renewed investments in long-acting therapies. According to DataM Intelligence, the Hepatitis B and C Therapeutics Market Size reached US$17.02 billion in 2024 and is forecast to grow steadily to US$20.83 billion by 2033, reflecting a CAGR of 3.4% (2025–2033). As the burden of chronic viral hepatitis continues to rise across high-income and emerging economies, pharmaceutical companies are shifting toward potent, shorter-duration therapies, improved compliance models, and immune-targeted drugs designed to deliver functional cures.

Growing disease prevalence-over 296 million people living with chronic Hepatitis B (HBV) and nearly 50 million with Hepatitis C (HCV) worldwide-combined with increased national-level commitments toward elimination by 2030 under WHO guidelines, has created substantial demand for reliable, clinically proven therapeutic options. With expanding access to screening technologies, improved diagnostics, and government-backed reimbursement pathways, the industry is seeing strong uptake of branded and generic therapies across hospital and retail distribution channels.

Buy This Report with Year-End Offer (Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50% OFF each! Limited time offer): https://www.datamintelligence.com/buy-now-page?report=hepatitis-b-and-c-therapeutics-market

Market Dynamics: Strong Push from Antiviral Innovation, Screening Mandates, and Real-World Evidence Programs

The market's expansion is driven by a combination of regulatory reforms, new product approvals, and the shift toward simplified, pan-genotypic therapies. The adoption of tenofovir and entecavir for HBV continues to remain robust, while the transition to direct-acting antivirals (DAAs) has transformed HCV care, reducing treatment durations from 24–48 weeks to as low as 8–12 weeks.

LSI keywords integrated: HBV therapeutics, HCV antivirals, chronic viral hepatitis drugs, DAA market, nucleotide analogues, liver disease burden, screening expansion, immunomodulators.

Key growth factors influencing the 2024–2033 outlook include:

Detailed Market Segmentation with 2024 Market Size and Shares

By Indication: Hepatitis B (HBV) vs. Hepatitis C (HCV)

In 2024, the market remained dominated by Hepatitis C therapeutics, supported by the strong commercial performance of direct-acting antivirals. Of the total US$17.02 billion market, HCV therapeutics accounted for approximately US$10.9 billion, representing 64% of global revenues. This dominance is driven by high cure rates, short treatment durations, and aggressive payer funding to eradicate the disease burden.

Meanwhile, Hepatitis B therapeutics generated nearly US$6.12 billion, accounting for 36% of the market in 2024. Despite lower growth relative to HCV, HBV therapeutics benefit from lifelong treatment regimens, rising vaccination uptake, and increasing research activity in functional cure mechanisms such as siRNA-based therapies, capsid assembly modulators, and T-cell immune enhancers.

By Route of Administration: Oral vs. Injectable Therapies

Oral formulations accounted for the largest share of the market in 2024, with revenues reaching US$13.21 billion, equivalent to 77.6% of global market value. The predominance of oral antivirals is linked to their effectiveness, patient convenience, and widespread availability across both retail and hospital channels.

Injectable therapeutics-including interferon-based therapy and novel immune-targeted biologics-represented US$3.81 billion, or 22.4%. Although historically declining, the segment has seen renewed interest in 2024 due to the development of long-acting immunotherapies for HBV functional cure programs.

By Distribution Channel: Hospital vs. Retail Pharmacies

Hospital pharmacies maintained a significant share of the market in 2024, contributing US$ 9.18 billion (54%) of total revenues as complex HCV regimens and high-risk HBV cases necessitated specialist intervention. Retail pharmacies accounted for US$ 7.84 billion (46%), supported by increased availability of DAAs through prescription-based community channels, especially in the U.S., Germany, and Japan.

Download PDF Brochure: https://www.datamintelligence.com/download-sample/hepatitis-b-and-c-therapeutics-market

Browse in-depth TOC on "Hepatitis B & C Therapeutics Market"

72 – Tables

67 – Figures

210 – Pages

Regional Analysis: Strong Momentum in the USA and Japan

United States Market Overview

The U.S. accounted for approximately 41% of the global hepatitis B and C therapeutics market in 2024, representing a market size of US$ 7.0 billion.

Key 2024–2025 quantitative drivers: